News
Video
Compounded GLP-1 RA drugs: GLP-1 RA drugs are no longer in shortage, but compounding customized versions of them may continue, part 1
APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.
The U.S. Food and Drug Administration has ruled GLP-1 RA drugs are no longer in shortage. That ruling affects how compounding pharmacists may mix those drugs. Scott Brunner, CAE, CEO of the Alliance for Pharmacy Compounding, explains the rules that compounding pharmacists operate under, especially for the antidiabetes and antiobesity drugs that have exploded in popularity.
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.
Related Videos
Related Content
